BR112018005208A2 - Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana - Google Patents
Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacterianaInfo
- Publication number
- BR112018005208A2 BR112018005208A2 BR112018005208A BR112018005208A BR112018005208A2 BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2 BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds containing
- heterocyclic compounds
- compositions useful
- mycobacterial infection
- useful against
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 2
- 206010062207 Mycobacterial infection Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220192P | 2015-09-17 | 2015-09-17 | |
US62/220,192 | 2015-09-17 | ||
PCT/US2016/052558 WO2017049321A1 (en) | 2015-09-17 | 2016-09-19 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018005208A2 true BR112018005208A2 (pt) | 2018-10-02 |
BR112018005208B1 BR112018005208B1 (pt) | 2023-12-12 |
Family
ID=58289763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018005208-6A BR112018005208B1 (pt) | 2015-09-17 | 2016-09-19 | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana |
Country Status (15)
Country | Link |
---|---|
US (2) | US10919888B2 (pt) |
EP (1) | EP3328382A4 (pt) |
JP (1) | JP7055378B2 (pt) |
KR (1) | KR20180053386A (pt) |
CN (1) | CN108348510B (pt) |
AU (2) | AU2016324598A1 (pt) |
BR (1) | BR112018005208B1 (pt) |
CA (1) | CA2998375A1 (pt) |
CL (1) | CL2018000688A1 (pt) |
HK (1) | HK1252225A1 (pt) |
IL (1) | IL257743B (pt) |
MX (2) | MX2018003294A (pt) |
PE (1) | PE20181352A1 (pt) |
WO (1) | WO2017049321A1 (pt) |
ZA (1) | ZA201802323B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3328382A4 (en) | 2015-09-17 | 2018-12-19 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
EP3464272B1 (en) | 2016-06-07 | 2021-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
KR102317480B1 (ko) | 2017-03-23 | 2021-10-25 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
CN108159049B (zh) * | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | 一种吡啶类化合物的新用途 |
JP2022536043A (ja) * | 2019-05-28 | 2022-08-12 | 塩野義製薬株式会社 | シトクロムbc1阻害剤とクラリスロマイシン又はアジスロマイシン及びクロファジミンを組み合わせることを特徴とするマイコバクテリア感染症治療用医薬 |
TW202124379A (zh) * | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的5,6-雜芳族化合物 |
CN114423758A (zh) * | 2019-09-13 | 2022-04-29 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
KR20220070489A (ko) * | 2019-09-26 | 2022-05-31 | 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. | 티아졸 카복사미드 화합물 및 미코박테리아 감염의 치료를 위한 이의 용도 |
WO2022119899A1 (en) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin |
WO2022194803A1 (en) * | 2021-03-16 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2525602A1 (fr) | 1982-04-21 | 1983-10-28 | Synthelabo | Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
FR2593818B1 (fr) | 1986-02-05 | 1988-04-29 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique |
DE4010797A1 (de) | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
DE4023215A1 (de) | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
JPH0539205A (ja) | 1990-12-21 | 1993-02-19 | Takeda Chem Ind Ltd | 農園芸用混合組成物 |
JP3026845B2 (ja) | 1991-02-20 | 2000-03-27 | 日清製粉株式会社 | ピペリジン誘導体 |
US5464843A (en) | 1992-06-23 | 1995-11-07 | G.D. Searle & Co. | Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury |
US5721273A (en) | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
AU2223495A (en) | 1994-04-15 | 1995-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Spiro compound and medicinal composition thereof |
EP0771319A1 (en) | 1994-07-15 | 1997-05-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
JPH09249666A (ja) | 1996-01-12 | 1997-09-22 | Takeda Chem Ind Ltd | 三環性化合物の製造法およびその中間体 |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
AUPP278498A0 (en) | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
WO1999063929A2 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
HUP0203954A2 (hu) | 1999-09-17 | 2003-03-28 | Millennium Pharmaceuticals, Inc. | Xa faktor inhibitorok |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
DK1277754T3 (da) | 2000-04-27 | 2005-11-14 | Astellas Pharma Inc | Imidazopyridinderivater |
US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
US20050113576A1 (en) | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
UA82577C2 (en) | 2003-12-23 | 2008-04-25 | Пфайзер Инк. | Quinoline derivatives |
WO2005108399A1 (ja) | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
US20060084806A1 (en) | 2004-07-21 | 2006-04-20 | Ramasubramanian Sridharan | Processes for the preparation of imidazo[1,2-a] pyridine derivatives |
EP1778685B1 (de) | 2004-08-02 | 2008-03-26 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
WO2006051063A1 (en) | 2004-11-11 | 2006-05-18 | Ferrer Internacional S. A. | Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto |
DE102005016547A1 (de) * | 2005-04-08 | 2006-10-12 | Grünenthal GmbH | Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
WO2007018998A2 (en) | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
AU2007254361A1 (en) | 2006-05-18 | 2007-11-29 | Merck Sharp & Dohme Corp. | Substituted esters as Cannabinoid-1 receptor modulators |
WO2008038251A2 (en) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
CN101553224A (zh) | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
JP2010513272A (ja) | 2006-12-14 | 2010-04-30 | メルク エンド カムパニー インコーポレーテッド | アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法 |
CA2672960A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
WO2008109177A2 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
EP1980251A1 (en) | 2007-04-13 | 2008-10-15 | Glaxo Group Limited | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis |
TW200901969A (en) | 2007-06-06 | 2009-01-16 | Smithkline Beecham Corp | Chemical compounds |
WO2009015208A1 (en) | 2007-07-23 | 2009-01-29 | Replidyne, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
AU2009208712B2 (en) | 2008-02-01 | 2013-03-14 | Orchid Chemicals & Pharmaceuticals Limited | Novel heterocycles |
CA2724842A1 (en) | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
WO2009148961A2 (en) | 2008-05-29 | 2009-12-10 | Wisconsin Alumni Research Foundation | Drugs to prevent hpv infection |
US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
CA2750635A1 (en) | 2009-02-23 | 2010-08-26 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2401275B1 (en) | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
CA2772714C (en) | 2009-09-03 | 2017-09-26 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
IN2012DN04917A (pt) | 2009-11-05 | 2015-09-25 | Univ Notre Dame Du Lac | |
CN102869661B (zh) | 2010-03-18 | 2015-08-05 | 韩国巴斯德研究所 | 抗感染化合物 |
EA022164B1 (ru) | 2011-02-25 | 2015-11-30 | Янссен Фармацевтика Нв | (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR |
KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
CA2836202A1 (en) * | 2011-05-30 | 2012-12-06 | Astellas Pharma Inc. | Imidazopyridine compounds |
BR112014010368A2 (pt) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
WO2014015167A2 (en) | 2012-07-18 | 2014-01-23 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
CA2891926A1 (en) | 2012-11-20 | 2014-05-30 | Merial, Inc. | Anthelmintic compounds and compositions and method of using thereof |
CA2891976C (en) * | 2012-11-30 | 2020-07-21 | Astellas Pharma Inc. | Imidazopyridine compounds |
ES2883565T3 (es) | 2013-08-02 | 2021-12-09 | Pasteur Institut Korea | Compuestos antiinfecciosos |
CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
EP3316969B1 (en) | 2015-07-02 | 2022-03-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
EP3328382A4 (en) | 2015-09-17 | 2018-12-19 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
EP3472158A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
MX2018015657A (es) | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
EP3266454A1 (en) | 2016-07-07 | 2018-01-10 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Acc inhibitors for use in treating mycobacterial diseases |
EP3589323B1 (en) | 2017-03-01 | 2024-04-03 | Janssen Sciences Ireland Unlimited Company | Combination therapy for the treatment of tuberculosis |
CN108159049B (zh) | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | 一种吡啶类化合物的新用途 |
US20210009583A1 (en) | 2018-03-12 | 2021-01-14 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
CN108358917B (zh) | 2018-04-24 | 2020-06-19 | 北京市结核病胸部肿瘤研究所 | 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 |
CN114423758A (zh) | 2019-09-13 | 2022-04-29 | 爱尔兰詹森科学公司 | 抗细菌化合物 |
-
2016
- 2016-09-19 EP EP16847573.9A patent/EP3328382A4/en not_active Withdrawn
- 2016-09-19 BR BR112018005208-6A patent/BR112018005208B1/pt active IP Right Grant
- 2016-09-19 WO PCT/US2016/052558 patent/WO2017049321A1/en active Application Filing
- 2016-09-19 CN CN201680063042.7A patent/CN108348510B/zh active Active
- 2016-09-19 US US15/760,939 patent/US10919888B2/en active Active
- 2016-09-19 AU AU2016324598A patent/AU2016324598A1/en not_active Abandoned
- 2016-09-19 CA CA2998375A patent/CA2998375A1/en active Pending
- 2016-09-19 MX MX2018003294A patent/MX2018003294A/es unknown
- 2016-09-19 IL IL257743A patent/IL257743B/en unknown
- 2016-09-19 PE PE2018000402A patent/PE20181352A1/es unknown
- 2016-09-19 KR KR1020187010743A patent/KR20180053386A/ko not_active Application Discontinuation
- 2016-09-19 JP JP2018514425A patent/JP7055378B2/ja active Active
-
2018
- 2018-03-15 MX MX2021000189A patent/MX2021000189A/es unknown
- 2018-03-15 CL CL2018000688A patent/CL2018000688A1/es unknown
- 2018-04-10 ZA ZA2018/02323A patent/ZA201802323B/en unknown
- 2018-09-06 HK HK18111462.6A patent/HK1252225A1/zh unknown
-
2020
- 2020-12-28 US US17/135,927 patent/US11820767B2/en active Active
-
2021
- 2021-06-14 AU AU2021203931A patent/AU2021203931A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2018000688A1 (es) | 2018-11-16 |
CA2998375A1 (en) | 2017-03-23 |
IL257743A (en) | 2018-04-30 |
RU2018111768A3 (pt) | 2020-02-20 |
US10919888B2 (en) | 2021-02-16 |
AU2016324598A1 (en) | 2018-03-15 |
JP2018532723A (ja) | 2018-11-08 |
BR112018005208B1 (pt) | 2023-12-12 |
CN108348510A (zh) | 2018-07-31 |
CN108348510B (zh) | 2022-01-04 |
US20210198254A1 (en) | 2021-07-01 |
WO2017049321A1 (en) | 2017-03-23 |
MX2021000189A (es) | 2021-03-25 |
EP3328382A4 (en) | 2018-12-19 |
JP7055378B2 (ja) | 2022-04-18 |
HK1252225A1 (zh) | 2019-05-24 |
MX2018003294A (es) | 2019-04-25 |
ZA201802323B (en) | 2019-01-30 |
RU2018111768A (ru) | 2019-10-17 |
KR20180053386A (ko) | 2018-05-21 |
IL257743B (en) | 2022-08-01 |
EP3328382A1 (en) | 2018-06-06 |
US11820767B2 (en) | 2023-11-21 |
US20180265506A1 (en) | 2018-09-20 |
PE20181352A1 (es) | 2018-08-22 |
AU2021203931A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005208A2 (pt) | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana | |
ES2964472T3 (es) | Composiciones que contienen ibrutinib | |
BR112017000039A2 (pt) | composições agrícolas e aplicações que utilizam óleos essenciais | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
DK3416996T3 (da) | Hærdelig sammensætning | |
DK3359241T3 (da) | Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf | |
BR112017016465A2 (pt) | composto heterocíclico e composição farmacêutica que o compreende | |
DK3388427T3 (da) | Derivater af dolastatin 10 og auristatiner | |
DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3083683T3 (da) | Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger | |
DK2777689T3 (da) | Ny farmaceutisk sammensætning til behandling af svampeinfektioner | |
DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
IL271550B (en) | A cyclic coumarin-like compound as a mek inhibitor and its use | |
DK3411008T3 (da) | Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren | |
EP3237413A4 (en) | Compositions of fatostatin based heterocyclic compounds and uses thereof | |
MA43166A (fr) | Formulation de fviii | |
DK3436029T3 (da) | Forbindelse indeholdende dexpanthenolglycosid | |
KR20180084930A (ko) | 접착제 조성물 및 구조체 | |
IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
DK3171873T3 (da) | Sammensætning omfattende en ester af alfa-tocopherol til forebyggelse og behandling af allergisk rhinitis | |
TWI839336B (zh) | 活性能量射線硬化性剝離型黏著劑組成物 | |
DK3654973T3 (da) | Sammensætninger mod candida-infektioner | |
DE112017004024A5 (de) | Silikonzusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2016, OBSERVADAS AS CONDICOES LEGAIS |